诺华肿瘤（中国）
Novartis Oncology (China)
诺华肿瘤以改善癌症及相关血液疾病患者的生活质量为己任，力争为尽可能多的患者提供更多的创新疗法以及解决方案，改善患者的疾病管理。诺华肿瘤隶属于诺华集团，总部位于瑞士巴赛尔，在全球85个国家拥有超过一万名员工 。
At Novartis Oncology, our mission is to enhance cancer and blood disorder patients’ quality of life, discover and develop breakthrough treatments and disease management methods, and find new ways to deliver them to as many people as possible. Headquartered in Basel, Switzerland, Novartis Oncology is a member of the Novartis Group, with over 10,000 associates in more than 85 countries.
诺华肿瘤业务在全球重点布局的五大领域包括乳腺癌、血液疾病、肺癌、黑色素瘤以及肾癌，同时积极开发新的、变革性的联合疗法，是目前唯一同时拥有靶向治疗、放射配体治疗、细胞和基因治疗以及免疫治疗丰富的产品线的医药公司。目前上市肿瘤药品超过25种，以及30种正在研发的 在肿瘤生物学上靶向作用于关键分子通路的新分子药物等。
Novartis Oncology has a strong presence in five key disease areas – breast cancer, lung cancer, melanoma, kidney cancer and hematology. We are reimagining medicine to transform cancer and blood disorders. We are the only pharmaceutical company with four distinct therapeutic platforms: targeted therapies, cell and gene therapy, immunotherapy and radioligand therapy. We currently have an unparalleled portfolio of therapies, with 25 drugs on the market and more than 30 new molecular entities in development targeting key molecular pathways in cancer biology.
在中国，诺华肿瘤主要专注于血液疾病、实体肿瘤以及罕见病领域，目前总计拥有超过1100名员工。在血液疾病治疗方面，目前覆盖的疾病包括慢性髓性白血病、骨髓纤维化、血小板减少症、地中海贫血症导致的铁过载等疾病；实体肿瘤覆盖的疾病包括乳腺癌、肺癌、肾细胞癌和黑色素瘤等；罕见病领域覆盖的疾病包括胃肠间质瘤、肢端肥大症与胃肠胰神经内分泌肿瘤等。
In China, with over 1,100 associates, Novartis Oncology focuses on hematology, solid tumors and rare disease therapeutic areas, including chronic myelogenous leukemia (CML), myelofibrosis (MF), immune thrombopenia (ITP) and iron overload (IOL) in hematology, as well as breast cancer, lung cancer, kidney cancer and melanoma solid tumors, and rare diseases of gastrointestinal stromal tumors (GIST), acromegaly (ARCO) and neuroendocrine tumors (NET).
诺华始终将患者健康置于首位。在中国，诺华积极配合国家为鼓励创新而推出的各项政策，加快新药引进。从2017年起，诺华肿瘤（中国）以每年1-3个新产品或新适应症的速度，把多个靶向治疗的创新药引入中国市场。
Patient health remains the first priority at Novartis. In China, we proactively comply with the government’s policies of innovation to speed up market access to new medicines. Since 2017, Novartis Oncology (China) has introduced between one and three new products or indications every year, bringing more target therapeutic treatments to the China market.
诺华肿瘤不仅通过研发、生产创新药物满足患者的治疗需求，同时探索提升可及性的创新路径，积极与政府和第三方开展合作，通过可持续的方式提高中国患者对药品的可及性。这些措施包括参与国家医保目录谈判、加速市场准入，采用创新支付、开展患者援助项目、推动疾病知识普及教育等等。截至2020年12月底为止，诺华肿瘤在华上市12个产品全部纳入医保范畴，与政府及各方一起协力造福患者，让更多患者早用上、用得起所需要的药物。
Novartis Oncology is not only satisfying patients’ unmet needs through research, development and the manufacture of innovative medicine. It is also proactively partnering with the government and third-party organizations, such as participating in National Reimbursement Drug List (NRDL) negotiations, accelerating market access, implementing innovative payment models, and conducting patient support programs and disease education, to improve patient access to innovative medicines in China. As of the end of December 2020, all 12 Novartis Oncology products marketed in China had been listed on the NRDL.
美迪康会务通